GlassScriptPhysician profile
Elizabeth L Robbins
NPI 1730151689
$1,858.47
in general payments reported to CMS, 2019-2025
21 companies · $65.59 in 2025
The $65.59 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146 · 2020: $254 · 2021: $294 · 2022: $330 · 2023: $338 · 2024: $432 · 2025: $65.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $834.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $324.24 | 2019-2024 | Jornay Pm |
| Cranial Technologies, INC | $274.60 | 2019-2025 | Doc Band |
| Tris Pharma INC | $272.52 | 2019-2024 | Dyanavel Xr |
| Kaleo, INC. | $189.70 | 2019-2024 | Auvi-Q |
| Corium, LLC | $104.19 | 2023-2024 | Azstarys |
| Adlon Therapeutics L.P. | $98.90 | 2020-2021 | |
| Vertical Pharmaceuticals, LLC | $96.24 | 2024-2025 | Relexxii |
| Merck Sharp & Dohme LLC | $90.88 | 2020-2023 | Gardasil 9, Vaxelis, Vaxneuvance |
| Takeda Pharmaceuticals U.S.A., INC. | $71.11 | 2021-2022 | |
| Pfizer INC. | $55.74 | 2019-2023 | |
| Sobi, INC | $45.90 | 2019-2023 | |
| Neos Therapeutics, LP | $41.80 | 2022-2023 | Adzenys Xr-Odt |
| Phadia US INC. | $37.35 | 2019-2023 | Immunocap |
| Astrazeneca Pharmaceuticals LP | $25.70 | 2024 | Flumist Quadrivalent |
| Hologic Sales and Service, LLC | $24.09 | 2024 | Aptima |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $23.98 | 2023 | |
| Collegium Pharmaceutical, INC. | $23.87 | 2025 | Jornay Pm |
| Seqirus USA INC | $15.24 | 2021 | |
| Horizon Therapeutics Plc | $14.41 | 2022 | |
| Aytu Biopharma, INC. | $14.35 | 2020 | |
| Supernus Pharmaceuticals, INC. | $13.66 | 2024 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Robbins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.